While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

An independent heart team blinded to ICA results was able to deliver helpful guidance for CABG procedures for 99.1% of patients using just CCTA and FFR_CT alone. This approach is safe and feasible, researchers wrote, and the next step is to gather additional data. 

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

Researchers explored data from nearly 70,000 patients, sharing their findings in the American Journal of Cardiology.

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.

"This finding suggests racial and gender bias as a potential contributor to the organ acceptance decision-making process," researchers wrote in JAMA.

Hoping to gain a better understanding of how TAVR may impact a patient’s long-term cardiovascular health, researchers explored data from more than 200,000 patients and shared their findings in JACC: Cardiovascular Interventions.

Members of Congress are now asking the FDA to investigate a parent's claim that her 14-year-old son was treated with an experimental heart valve without proper consent. The valve eventually failed and had to be replaced. The hospital has said its heart team did nothing wrong.